Mississippi Legislature Bypasses Advisory Council in Allocating Opioid Settlement Funds

Mississippi lawmakers have advanced a contentious plan to allocate nearly $60 million in opioid settlement funds, largely bypassing the independent advisory council the Legislature itself created just last year to provide oversight and expertise in distributing the money.

Senate Bill 2726, passed March 30 after late-night negotiations, grants legislators significantly more authority to modify or reject the council's recommendations while simultaneously weakening the council's role in determining how hundreds of millions of settlement dollars will be spent over the next decade and a half.

The move has sparked sharp criticism from public health advocates, transparency groups, and even some legislators who argue the process undermines the purpose of establishing an independent council and raises questions about whether Mississippi's opioid settlement funds will reach the communities most devastated by the crisis.

Settlement Funds and Legislative Control

Mississippi expects to receive approximately $421 million through 2040 from national settlements with pharmaceutical manufacturers, distributors, and pharmacy chains accused of fueling the opioid epidemic. The Legislature controls roughly 85 percent of these funds—about $357 million—while the remaining 15 percent flows to local governments.

When the first settlement payments arrived in 2022, Mississippi stood out among states for the lack of structure around fund distribution. While other states established dedicated commissions, engaged community stakeholders, and developed strategic plans, Mississippi's settlement dollars sat largely untouched for more than three years.

In response to mounting criticism, the Legislature passed a law in 2025 creating the Mississippi Opioid Settlement Fund Advisory Council. The statute instructed that lawmakers spend most of the money with the council's advice, permitting legislators only to accept or reject its recommendations—not to rewrite them or selectively implement portions.

The council, composed of public health experts, addiction treatment providers, law enforcement representatives, and individuals with lived experience of substance use disorder, spent months developing a comprehensive spending plan. Members reviewed applications from community organizations, consulted data on overdose deaths and treatment gaps, and ultimately submitted detailed recommendations to the Legislature last winter.

Senate Bill 2726 effectively sets those recommendations aside. The spending plan released by House and Senate negotiators late Friday, March 28, bears little resemblance to what the council proposed. Instead, lawmakers crafted their own allocation strategy, redirecting funds to different programs and purposes than those the council identified as priorities.

"Rube Goldberg on LSD"

The convoluted process drew withering criticism from Senator Hob Bryan, who described the measure as something "Rube Goldberg on LSD could not have come up with." His remarks captured widespread frustration with a legislative maneuver that simultaneously maintains the advisory council in name while stripping much of its authority in practice.

Under the revised framework, the Legislature gains power to adjust the council's recommendations before voting, rather than facing a simple up-or-down choice. The change fundamentally alters the council's role from independent arbiter of evidence-based spending to advisory body whose input legislators can selectively embrace or ignore.

Proponents of the bill argue the changes strengthen accountability by ensuring elected officials retain final decision-making authority over public funds. They note the legislation also introduces stricter ethics rules intended to prevent conflicts of interest among council members—a response to controversy last fall when several members recommended directing funds to organizations they were affiliated with.

Critics counter that if legislators wanted ultimate control, they shouldn't have created an independent council in the first place. The current approach, they argue, produces the worst of both worlds: a process that appears to incorporate expert guidance while actually allowing political considerations to override public health priorities.

The Stakes: Overdose Crisis Continues

The debate unfolds against a backdrop of persistent crisis. The Mississippi State Department of Health counted more than 4,600 non-fatal overdoses in just the first six months of 2025—a staggering figure for a state with a population under three million. Many of those overdoses involved fentanyl, the synthetic opioid that has become the dominant driver of opioid deaths nationwide since 2020.

Access to evidence-based treatment remains limited across much of Mississippi. Medication-assisted treatment using buprenorphine or methadone—the gold standard for opioid use disorder—is difficult to obtain in rural areas where the nearest provider may be an hour or more away. Harm reduction services, including naloxone distribution and syringe exchange programs, face ongoing stigma and political opposition despite strong evidence of effectiveness.

These are precisely the gaps the opioid settlement funds were meant to address. Every dollar directed toward programs without evidence of effectiveness, or diverted to purposes unrelated to addiction treatment and prevention, represents a missed opportunity to save lives.

The advisory council's original recommendations emphasized expanding medication-assisted treatment access, funding peer recovery support services, increasing naloxone availability, and supporting programs addressing the specific needs of pregnant and postpartum women with substance use disorders. Whether the Legislature's alternative spending plan will address these priorities remains unclear, as detailed budget documents have not been made publicly available.

Transparency Concerns

One persistent criticism of Mississippi's handling of settlement funds involves transparency—or the lack thereof. The 15 percent of settlement money controlled by towns, cities, and counties is unrestricted and being spent with almost no public disclosure.

Unlike the state-controlled portion, which at least goes through the legislative appropriations process, local government spending decisions happen with minimal reporting requirements. Some municipalities have used the funds for opioid abatement efforts; others have directed the money to unrelated purposes or haven't spent it at all. The public largely has no way to know which is which.

Senate Bill 2726 includes a provision instructing the Attorney General's office to contract with a third-party organization to improve Mississippi's opioid settlement distribution and evaluation. The contract would come from the $63 million allocated to local governments, effectively redirecting a portion of those unrestricted funds toward oversight and accountability measures.

Whether that provision survives implementation remains to be seen. The Legislature can instruct the Attorney General's office to prioritize such a contract, but lawmakers cannot compel local governments that control their own portions of the settlement to participate in evaluation or transparency initiatives they oppose.

National Context: How Other States Approach Settlement Spending

Mississippi's struggle with opioid settlement allocation is not unique, but the specific dysfunction appears more pronounced than in many peer states.

West Virginia, which faces the nation's highest overdose death rate, recently commissioned West Virginia University to conduct an 18-month data-driven assessment before allocating its $1 billion in settlement funds. The effort aims to identify treatment gaps, measure existing service capacity, and create an interactive dashboard allowing the public to track how funds are spent and what outcomes result.

Georgia's Cobb County established a competitive review process for its $15.6 million settlement share, engaging both an independent evaluation team and a community advisory council before awarding $5.8 million to ten organizations in its first funding round. The transparent process allowed rejected applicants to understand why their proposals weren't selected and refine applications for future rounds.

Pennsylvania created a comprehensive opioid abatement trust, pooling state and local funds under unified governance with clear spending priorities aligned to evidence-based interventions. The structure ensures coordination across jurisdictions and prevents the patchwork approach that can leave some counties well-resourced while neighbors struggle.

By contrast, Mississippi's approach—creating an advisory council, soliciting expert recommendations, then largely disregarding that guidance while maintaining the council as window dressing—risks the appearance of process without the substance of meaningful expert input.

What Happens Next

With Senate Bill 2726 passed, the Legislature's opioid settlement spending plan moves to implementation. Approximately $60 million from the current allocation cycle will flow to programs and purposes determined by lawmakers, with the advisory council relegated to a consultative role stripped of the authority members understood they possessed when agreeing to serve.

Some council members may resign in protest, concluding their participation provides political cover for a process they cannot meaningfully influence. Others may remain, hoping to exert whatever modest influence the diminished role permits. Either way, the council as originally conceived—an independent body of experts guiding evidence-based spending—no longer exists in practice, whatever the statute claims in theory.

For Mississippians struggling with opioid addiction, the political maneuvering may seem abstract compared to the daily reality of trying to access treatment, avoid relapse, or prevent a loved one's next overdose. But the consequences are concrete: settlement dollars directed toward ineffective programs or diverted to unrelated purposes won't expand medication-assisted treatment access, won't train peer recovery specialists, won't distribute naloxone to communities where overdoses are spiking.

The opioid crisis that generated these settlement funds killed hundreds of thousands of Americans over two decades. Mississippi's share of the settlement money—$421 million spread across 14 years—represents a once-in-a-generation opportunity to build treatment infrastructure, support recovery services, and implement prevention programs that could spare future generations the devastation already endured.

Whether the Legislature's decision to sidestep expert guidance and centralize allocation decisions proves wise or wasteful will become clear in the years ahead, measured not in political pronouncements but in overdose statistics, treatment wait times, and the lived experiences of people seeking help.

The council's recommendations offered one path forward, grounded in public health evidence and community input. Legislators chose a different route. Time will tell which approach serves Mississippi better—or whether the opportunity these settlement funds represent will be squandered while communities continue to bury their dead.